Optimizing rare neurological disease trials: Bayesian frameworks and hierarchical models for improved efficiency in clinical trial design
- 24 May 2026
- journal article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- p. 1-13
Abstract
While traditionally used in early-phase oncology trials, we explore the benefits of Bayesian methods in clinical trial design, emphasizing their application in rare neurological disease trials. Focusing in this report on a potential redesign of the Phase II trial of SAR445088 in chronic inflammatory demyelinating polyneuropathy (CIDP), we compare the performance of the original design to two potential optimization alternatives. First, we retained continuous outcomes to preserve information. In the second modification, we propose the use of information borrowing through Bayesian hierarchical models (BHM). BHM for subgroup analysis increase precision in individual subpopulations by borrowing information from the whole study population and pooling individual estimates towards the overall estimate. Such models are used in basket trials which aim to evaluate a single targeted therapy across multiple settings that share a common characteristic. We found that the proposed optimizations demonstrate notable power gains. We advocate enhancing the efficiency of neurological disorders research through the implementation of this optimized Bayesian approach.Keywords
This publication has 26 references indexed in Scilit:
- Predicting dichotomised outcomes from high-dimensional data in biomedicineJournal of Applied Statistics, 2023
- Bayesian borrowing for basket trials with longitudinal outcomesStatistics in Medicine, 2023
- Categories, components, and techniques in a modular construction of basket trials for application and further researchBiometrical Journal, 2021
- Making Continuous Measurements into Dichotomous VariablesPM&R, 2019
- Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trialThe Lancet Neurology, 2018
- Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Neurology, 2018
- Use of historical control data for assessing treatment effects in clinical trialsPharmaceutical Statistics, 2013
- Dichotomising continuous data while retaining statistical power using a distributional approachStatistics in Medicine, 2012
- Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trialThe Lancet Neurology, 2008
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001